Pramipexole, a Dopamine D2/D3 Receptor-Preferring Agonist, Prevents Experimental Autoimmune Encephalomyelitis Development in Mice.

Mol Neurobiol

Laboratory of Autoimmunity and Immunopharmacology, Campus Araranguá, Universidade Federal de Santa Catarina, Rodovia Jorge Lacerda, Km 35,4, Jardim das Avenidas, 88906-072, Araranguá, SC, Brazil.

Published: March 2017

AI Article Synopsis

  • Experimental autoimmune encephalomyelitis (EAE) is a key animal model for studying multiple sclerosis (MS) and testing new treatments, with dopamine receptors showing potential effects on EAE and MS progression.
  • The study investigates pramipexole (PPX), a drug typically used for Parkinson's disease, and finds that it can prevent EAE development by reducing neuroinflammation and demyelination in the spinal cord.
  • Results indicate that PPX effectively lowers harmful inflammatory cytokines and restores normal levels of various cellular responses, suggesting its potential as a therapeutic approach for managing EAE and possibly MS.

Article Abstract

Experimental autoimmune encephalomyelitis (EAE) is the most used animal model of multiple sclerosis (MS) for the development of new therapies. Dopamine receptors can modulate EAE and MS development, thus highlighting the potential use of dopaminergic agonists in the treatment of MS, which has been poorly explored. Herein, we hypothesized that pramipexole (PPX), a dopamine D2/D3 receptor-preferring agonist commonly used to treat Parkinson's disease (PD), would be a suitable therapeutic drug for EAE. Thus, we report the effects and the underlying mechanisms of action of PPX in the prevention of EAE. PPX (0.1 and 1 mg/kg) was administered intraperitoneally (i.p.) from day 0 to 40 post-immunization (p.i.). Our results showed that PPX 1 mg/kg prevented EAE development, abolishing EAE signs by blocking neuroinflammatory response, demyelination, and astroglial activation in spinal cord. Moreover, PPX inhibited the production of inflammatory cytokines, such as IL-17, IL-1β, and TNF-α in peripheral lymphoid tissue. PPX was also able to restore basal levels of a number of EAE-induced effects in spinal cord and striatum, such as reactive oxygen species, glutathione peroxidase, parkin, and α-synuclein (α-syn). Thus, our findings highlight the usefulness of PPX in preventing EAE-induced motor symptoms, possibly by modulating immune cell responses, such as those found in MS and other T helper cell-mediated inflammatory diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12035-016-9717-5DOI Listing

Publication Analysis

Top Keywords

dopamine d2/d3
8
d2/d3 receptor-preferring
8
receptor-preferring agonist
8
experimental autoimmune
8
autoimmune encephalomyelitis
8
eae development
8
ppx 1 mg/kg
8
spinal cord
8
ppx
7
eae
6

Similar Publications

Objectives: Clozapine is an atypical antipsychotic crucial for treatment-resistant schizophrenia, characterised by its multi-receptor targeting, including serotonin (5-HT2A, 5-HT2C) and dopamine (D1, D2, D3, D4) receptors, among others. This broad mechanism is effective against positive symptoms of schizophrenia with a lower incidence of extrapyramidal side effects. However, clozapine poses significant haematological risks, notably agranulocytosis, necessitating stringent blood monitoring protocols.

View Article and Find Full Text PDF

Ultradian Rest-activity Rhythms Induced by Quinpirole in Mice Using Wavelet Analysis.

Clin Psychopharmacol Neurosci

November 2024

Department of Pediatrics, College of Medicine, Kosin University, Busan, Korea.

Objective: Ultradian rhythms are biological rhythms with periods of a few seconds to a few hours. Along with circadian rhythms, ultradian rhythms influence human physiology. However, such rhythms have not been studied as intensively as circadian rhythms.

View Article and Find Full Text PDF

Cariprazine in Psychiatry: A Comprehensive Review of Efficacy, Safety, and Therapeutic Potential.

Med Sci Monit

September 2024

II Department of Psychiatry and Psychiatric Rehabilitation, Faculty of Medicine, Medical University of Lublin, Lublin, Poland.

Article Synopsis
  • * Cariprazine uniquely acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, improving symptoms such as negative effects in schizophrenia and exhibiting antidepressant properties.
  • * It shows effectiveness in managing both manic and depressive episodes in bipolar disorder, has a favorable safety profile, and ongoing research may unveil its benefits in pediatric populations and addiction therapy.
View Article and Find Full Text PDF

Pramipexole Hyperactivates the External Globus Pallidus and Impairs Decision-Making in a Mouse Model of Parkinson's Disease.

Int J Mol Sci

August 2024

Division of Behavioral Neuropharmacology, International Center for Brain Science (ICBS), Fujita Health University, Toyoake 470-1192, Aichi, Japan.

In patients with Parkinson's disease (PD), dopamine replacement therapy with dopamine D2/D3 receptor agonists induces impairments in decision-making, including pathological gambling. The neurobiological mechanisms underlying these adverse effects remain elusive. Here, in a mouse model of PD, we investigated the effects of the dopamine D3 receptor (D3R)-preferring agonist pramipexole (PPX) on decision-making.

View Article and Find Full Text PDF

Cariprazine in the management of emotionally unstable personality disorder in female patients: a case series.

Front Psychiatry

July 2024

Department of Psychiatry, West London National Health Service (NHS) Trust, London, United Kingdom.

Background: Emotionally unstable personality disorder (EUPD) is debilitating psychiatric disorder, particularly common in female and forensic populations. However, appropriate pharmacological treatment to effectively manage symptoms of EUPD remains an unmet clinical need. Dopamine receptor partial agonists (DRPAs), such as aripiprazole, have a favourable tolerability profile and have demonstrated some benefits in targeting symptoms of emotional dysregulation, although, evidence regarding the effects of novel D2/D3 DRPA cariprazine in EUPD patients has been limited.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!